[go: up one dir, main page]

WO2005085867A8 - Screening method for emulators of neural activity and digestive system using gpr35 - Google Patents

Screening method for emulators of neural activity and digestive system using gpr35

Info

Publication number
WO2005085867A8
WO2005085867A8 PCT/IB2005/000382 IB2005000382W WO2005085867A8 WO 2005085867 A8 WO2005085867 A8 WO 2005085867A8 IB 2005000382 W IB2005000382 W IB 2005000382W WO 2005085867 A8 WO2005085867 A8 WO 2005085867A8
Authority
WO
WIPO (PCT)
Prior art keywords
gpr35
screening method
receptor
emulators
digestive system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2005/000382
Other languages
French (fr)
Other versions
WO2005085867A2 (en
WO2005085867A3 (en
Inventor
Yasuhito Taniguchi
Hiroko Kachi
Kimihiko Tomotoshi
Katsuhiro Shinjo
Tohru Komada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Priority to CA002558721A priority Critical patent/CA2558721A1/en
Priority to EP05702505A priority patent/EP1720530A2/en
Publication of WO2005085867A2 publication Critical patent/WO2005085867A2/en
Publication of WO2005085867A3 publication Critical patent/WO2005085867A3/en
Publication of WO2005085867A8 publication Critical patent/WO2005085867A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention primarily relates to function analysis of GPR35, an orphan GPCR (G protein coupled receptor), a screening method to identify modulators (agonists/antagonists) of the receptor, cells stably expressing the receptor, and the discovery of modulators of the receptor. The present invention also relates to novel rat GPR35.
PCT/IB2005/000382 2004-02-27 2005-02-14 Screening method for emulators of neural activity and digestive system using gpr35 Ceased WO2005085867A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002558721A CA2558721A1 (en) 2004-02-27 2005-02-14 Screening method for emulators of neural activity and digestive system using gpr35
EP05702505A EP1720530A2 (en) 2004-02-27 2005-02-14 Screening method for emulators of neural activity and digestive system using gpr35

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54871904P 2004-02-27 2004-02-27
US60/548,719 2004-02-27

Publications (3)

Publication Number Publication Date
WO2005085867A2 WO2005085867A2 (en) 2005-09-15
WO2005085867A3 WO2005085867A3 (en) 2006-04-20
WO2005085867A8 true WO2005085867A8 (en) 2006-06-22

Family

ID=34919394

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/000382 Ceased WO2005085867A2 (en) 2004-02-27 2005-02-14 Screening method for emulators of neural activity and digestive system using gpr35

Country Status (3)

Country Link
EP (1) EP1720530A2 (en)
CA (1) CA2558721A1 (en)
WO (1) WO2005085867A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625707B2 (en) 2003-10-02 2009-12-01 Ramot At Tel Aviv University Ltd. Antibacterial agents and methods of identifying and utilizing same
US8927689B2 (en) 2002-12-09 2015-01-06 Ramot At Tel-Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
US9394628B2 (en) 2004-08-02 2016-07-19 Ramot At Tel-Aviv University Ltd. Method of forming a fiber made of peptide nanostructures

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1793816B1 (en) * 2004-08-19 2012-01-04 Tel Aviv University Future Technology Development L.P. Compositions for treating amyloid associated diseases
EP1973928A2 (en) 2005-10-11 2008-10-01 Ramot at Tel-Aviv University Ltd. Self-assembled fmoc-ff hydrogels
US9040583B2 (en) 2009-07-22 2015-05-26 Temple University-Of The Commonwealth System Of Higher Education Treatment of disorders associated with G protein-coupled receptor 35 (GPR35)
US20120022116A1 (en) * 2010-07-20 2012-01-26 Huayun Deng Compositions and methods for the treatment of pathological condition(s) related to gpr35 and/or gpr35-herg complex
CN113194961A (en) * 2018-12-21 2021-07-30 格礼卡姆股份公司 Compositions and methods for promoting intestinal barrier healing
TWI845600B (en) * 2019-01-24 2024-06-21 美商普羅米修斯生物科學股份有限公司 Gpr35 modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403305B1 (en) * 1997-02-06 2002-06-11 Cornell Research Foundation, Inc. Methods of identifying peptide agonists or negative antagonists of a G protein coupled receptor
WO1999064452A1 (en) * 1998-06-11 1999-12-16 Smithkline Beecham Corporation Gpr35a receptor
WO2000008155A2 (en) * 1998-08-07 2000-02-17 Incyte Pharmaceuticals, Inc. Human receptor-associated proteins
US20050075494A1 (en) * 2000-12-18 2005-04-07 Liu Qingyun Isolated nucleic acid molecules encoding a human and mouse g protein-coupled receptor-gpr54: encoded proteins, cells transformed therewith and uses thereof
WO2002061087A2 (en) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
JP2006513702A (en) * 2002-09-09 2006-04-27 ヌラ インコーポレーティッド G protein-coupled receptor and use thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8927689B2 (en) 2002-12-09 2015-01-06 Ramot At Tel-Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
US7625707B2 (en) 2003-10-02 2009-12-01 Ramot At Tel Aviv University Ltd. Antibacterial agents and methods of identifying and utilizing same
US9394628B2 (en) 2004-08-02 2016-07-19 Ramot At Tel-Aviv University Ltd. Method of forming a fiber made of peptide nanostructures

Also Published As

Publication number Publication date
EP1720530A2 (en) 2006-11-15
CA2558721A1 (en) 2005-09-15
WO2005085867A2 (en) 2005-09-15
WO2005085867A3 (en) 2006-04-20

Similar Documents

Publication Publication Date Title
WO2018056821A8 (en) Binding molecules that modulate a biological activity expressed by a cell
WO2005085867A3 (en) Screening method for emulators of neural activity and digestive system using gpr35
WO2007092938A3 (en) Cellular assays for signaling receptors
WO2000021987A3 (en) A method of identifying modulators of cell surface membrane receptors useful in the treatment of disease
WO2006000830A3 (en) Cells expressing a modified t cell receptor
Hauser et al. Novel approaches leading towards peptide GPCR de‐orphanisation
SG11201804563SA (en) Digital microfluidic system for single-cell isolation and characterization of analytes
WO2005020924A3 (en) A rapid way to obtain high expression clones of mammalian cells using a methylcellulose and immunoprecipitation screening method
IL179427A0 (en) Antibodies as t cell receptor mimics, methods of production and uses thereof
WO2005076887A3 (en) Methods and systems for sampling, screening, and diagnosis
WO2009055509A3 (en) Cholesterol consensus motif of membrane proteins
WO2006031883A3 (en) Analysis of mhc-peptide binding interactions
WO2006094704A3 (en) Natural ligand of g protein coupled receptor rcc356 and uses thereof
WO2003095606A3 (en) A t cell subpopulation regulating gut immunity
WO2008028068A3 (en) NON-HUMAN PRIMATE FCεR1α POLYPEPTIDES
NZ524693A (en) Methods for identifying VPAC receptor agonists for treating muscle atrophy using vasoactive intestinal peptide receptors
WO2004037160A3 (en) In vitro test for studying compound predicting pharmacologic and/or pharmacokinetic and/or pharmacodynamic parameters of a compound
WO2007039507A3 (en) Methods of identifying antibodies to ligands of orphan receptors
EP1340979A3 (en) Neuropeptide receptor and uses thereof
WO2004009770A3 (en) Methods and compositions for modulating agonist-induced downregulation of g protein-coupled receptors
WO2004083803A3 (en) Test methods for determining the intracellular concentration of cyclic nucleotides
Gerelsaikhan et al. Biogenesis and Topology of the Secretory Na+− K+− 2Cl-Cotransporter (NKCC1) Studied in Intact Mammalian Cells
WO2001067106A3 (en) Identification of g protein-coupled receptor ligands and modulators
AU2003291608A1 (en) A method of drug screening to select agonists or antagonists of g protein coupled receptors (gpcr).
WO2007140308A3 (en) Methods of screening for trpm4 modulators of insulin secretion

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page

Free format text: UNDER (54) PUBLISHED TITLE REPLACED BY CORRECT TITLE

WWE Wipo information: entry into national phase

Ref document number: 2558721

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005702505

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/009534

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2007500310

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2005702505

Country of ref document: EP

ENP Entry into the national phase in:

Ref document number: PI0508011

Country of ref document: BR

WWW Wipo information: withdrawn in national office

Ref document number: 2005702505

Country of ref document: EP